Reata Pharmaceuticals Inc (NASDAQ:RETA) CAO Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $194.24, for a total transaction of $388,480.00. Following the completion of the sale, the chief accounting officer now owns 17,146 shares in the company, valued at approximately $3,330,439.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Elaine Castellanos also recently made the following trade(s):

  • On Monday, October 28th, Elaine Castellanos sold 4,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $200.00, for a total transaction of $800,000.00.
  • On Friday, October 25th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $190.00, for a total value of $380,000.00.
  • On Friday, October 18th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $170.00, for a total transaction of $340,000.00.
  • On Monday, October 14th, Elaine Castellanos sold 3,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $105.00, for a total transaction of $315,000.00.
  • On Friday, September 6th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $85.00, for a total value of $170,000.00.

Shares of RETA opened at $202.65 on Wednesday. The firm has a market cap of $5.93 billion, a P/E ratio of -70.61 and a beta of 2.64. Reata Pharmaceuticals Inc has a 1 year low of $47.50 and a 1 year high of $222.33. The company has a 50 day simple moving average of $195.85 and a two-hundred day simple moving average of $113.19.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.07). The company had revenue of $8.24 million for the quarter, compared to analysts’ expectations of $7.43 million. Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,281.61%. The business’s revenue was up 59.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.07) earnings per share. As a group, equities research analysts expect that Reata Pharmaceuticals Inc will post -5.35 EPS for the current year.

A number of analysts have commented on RETA shares. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. Cantor Fitzgerald upped their target price on shares of Reata Pharmaceuticals from $250.00 to $314.00 in a research note on Wednesday, November 27th. BidaskClub upgraded shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 2nd. LADENBURG THALM/SH SH reiterated a “positive” rating and set a $239.00 target price (up from $133.00) on shares of Reata Pharmaceuticals in a research report on Wednesday, October 16th. Finally, Robert W. Baird boosted their price objective on Reata Pharmaceuticals from $162.00 to $245.00 and gave the company a “positive” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Reata Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $255.63.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amundi Pioneer Asset Management Inc. boosted its position in shares of Reata Pharmaceuticals by 37.1% during the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 183,919 shares of the company’s stock valued at $17,353,000 after acquiring an additional 49,814 shares during the last quarter. Farallon Capital Management LLC raised its holdings in shares of Reata Pharmaceuticals by 6.7% in the second quarter. Farallon Capital Management LLC now owns 800,000 shares of the company’s stock worth $75,480,000 after buying an additional 50,000 shares during the period. Dupont Capital Management Corp bought a new stake in shares of Reata Pharmaceuticals during the 3rd quarter worth approximately $283,000. Optimum Investment Advisors bought a new position in Reata Pharmaceuticals in the 2nd quarter valued at $76,000. Finally, DekaBank Deutsche Girozentrale increased its stake in Reata Pharmaceuticals by 512.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 45,300 shares of the company’s stock worth $4,147,000 after purchasing an additional 37,900 shares during the period. 60.04% of the stock is owned by institutional investors and hedge funds.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Recommended Story: What are momentum indicators and what do they show?

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.